Coronavirus disease (COVID-19) is a serious illness caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The symptoms of the disease range from …

Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in
the United States with an annual incidence of approximately 1 million. Dual antiplatelet …

Background The American College of Chest Physicians Clinical Practice Guideline on the
Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions …

Aims Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS)
vs. clopidogrel. We wished to study clinical outcomes in a large real-world population post …

Fluorine mass balance studies have shown that monomeric per-and polyfluoroalkyl
substances (PFAS) with perfluoroalkyl chain lengths of∼ 5–14 carbon atoms …

The P2Y12 receptor is a key player in platelet activation and a major target for antithrombotic
drugs. The beneficial effects of P2Y12 receptor antagonists might, however, not be restricted …

The first international guidance on antithrombotic therapy in the elderly came from the
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …

Background Ticagrelor is an oral antiplatelet drug that can reversibly bind to the platelet
P2Y12 receptor. Ticagrelor is metabolized mainly by CYP3A4 and produces a rapid blood …

The objective of the study was to fabricate tailored extended‐release tablets of blood thinner
Ticagrelor as once‐daily dosing using additive manufacturing for better compliance in heart …

Aims The antiplatelet treatment strategy providing optimal balance between thrombotic and
bleeding risks in patients undergoing coronary artery bypass grafting (CABG) is unclear. We …